For those interested Morgan's released the following on CSL:
DJ Market Concerns Over CSL's Vifor Pharma Deal May Be Misplaced -- Market Talk
CSL$273.00-$24.27 (-8.2%)$272.99$273.00
16 Dec 2021 15:17:4211 Views0416 GMT - Concerns around CSL's US$11.7 billion takeover of Switzerland-based specialty drug maker Vifor Pharma look overdone to Morgans.
The investment bank acknowledges that the strategic rationale may be hard for some investors to get their heads around, and perhaps wonder if CSL's core plasma business could struggle to keep growing.
"But we believe this is misplaced as this deal looks as unique as CSL itself, allowing access to a defensible specialty product portfolio with strong market positions and growth opportunities, far from a 'typical' pharma transaction," says Morgans, which rates CSL as add. ([email protected]; @dwinningWSJ)
(END) Dow Jones Newswires
December 15, 2021 23:17 ET (04:17 GMT)